A new programme to boost research on cancers prevalent in Asia will give the region a stronger foothold in drug development, expedite drug approvals and improve patient access to innovative medications.
Genome sequencing has given rise to possibilities for targeted therapy in many diseases. By predicting who might respond to a particular therapy, based on their own cancer’s genetic profile, it is easier to select a treatment that is more likely to be effective, offer longer survival and keep quality of life high. Radha Chitale discussed the evolution and potential of personalized cancer care with Dr. William Nelson, director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, Maryland, US.
Extracted from a speech presented by Dr. Saunthari Somasundaram, president and medical director of the National Cancer Society of Malaysia, at the opening of the inaugural World Cancer Day Conference and Expo 2014, Kuala Lumpur, 22 February
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.